Praeventix Inc.

Praeventix Inc. is an early development stage biopharmaceutical company based in Exton, Pennsylvania, in the United States. The company is focused on the discovery, research and clinical development of novel serotonergic therapeutics — medicines that act on the serotonin (5-HT) system — with potential applications in dermatologic, autoimmune and neurodegenerative diseases. Its lead program centers on the 5-HT7 receptor, a serotonin receptor subtype that the company believes plays a central role in itch transduction and in other serotonergic-driven conditions. Praeventix was founded by Dr. Douglas Pippin, based on discoveries he researched at Temple University. The company describes itself as pursuing potential first-in-class treatments, with its initial focus on the clinical candidate PRA-523, a neuromodulatory 5-HT7 receptor antagonist being developed for the treatment of chronic pruritus. Chronic pruritus, defined as itch lasting more than six weeks, is described by the company as having an estimated lifetime prevalence of more than 20% in the general population and as a global health concern with limited therapeutic options. Beyond chronic pruritus, Praeventix is researching 5-HT7 modulators for the potential treatment of inflammatory bowel disease (IBD) and cocaine use disorder (CUD). The company positions serotonin as a central mediator of itch, with transduction occurring along serotonergic sensory afferent neurons in the skin, and it highlights the significant impact of chronic itch on sleep, mood, personal relationships and quality of life. Its stated mission is to improve the quality of life for those who suffer from serotonergic-driven disorders. As an early-stage private company, Praeventix is not publicly listed and does not disclose a parent company or larger corporate group. Its activities are concentrated in the United States, where it conducts its discovery and development work.

Praeventix Inc. is an early development stage biopharmaceutical company headquartered in Exton, Pennsylvania, United States. The company was founded by Dr. Douglas Pippin, based on discoveries he researched at Temple University. Its scientific foundation rests on the serotonin (5-HT) system, and specifically on the 5-HT7 receptor subtype, which the company is pursuing as a target for novel therapeutics. From its inception, Praeventix has concentrated on serotonergic-driven disorders. Its stated mission is to improve the quality of life for those who suffer from such disorders, and it describes itself as committed to the discovery, research and clinical development of novel serotonergic therapeutics with potential applications in dermatologic, autoimmune and neurodegenerative diseases. The company's lead program is the clinical candidate PRA-523, described as a potential first-in-class neuromodulatory 5-HT7 receptor antagonist for the treatment of chronic pruritus. Chronic pruritus — itch lasting more than six weeks — is characterized by the company as a symptom of many diseases and the most common skin complaint in dermatology, with an estimated lifetime prevalence of more than 20% in the general population. Praeventix notes that serotonin is a central mediator of itch, with transduction occurring along serotonergic sensory afferent neurons in the skin, and that chronic itch affects sleep, mood and personal relationships, significantly reducing quality of life in a manner similar to chronic pain. The company also points to an unmet need in atopic dermatitis, where chronic pruritus is described as a trademark symptom. In addition to chronic pruritus, Praeventix is researching 5-HT7 modulators for the potential treatment of inflammatory bowel disease (IBD) and cocaine use disorder (CUD), extending its serotonergic platform beyond dermatology into gastrointestinal and neuropsychiatric indications. As of the available public information, Praeventix remains a private, early-stage company. It is not publicly listed, and no parent company or larger corporate group is disclosed. Its operations and development activities are based in the United States.

• Praeventix founded by Dr. Douglas Pippin based on discoveries researched at Temple University.

• Company focuses on development of clinical candidate PRA-523, a 5-HT7 receptor antagonist for chronic pruritus.

• Praeventix expands research into 5-HT7 modulators for inflammatory bowel disease (IBD) and cocaine use disorder (CUD).

Early development stage biopharmaceutical company developing potential first-in-class serotonergic therapeutics, initially targeting chronic pruritus.

• PRA-523

  Potential first-in-class neuromodulatory 5-HT7 receptor antagonist for the treatment of chronic pruritus.

• 5-HT7 modulators for IBD

  Research-stage 5-HT7 modulators for the potential treatment of inflammatory bowel disease.

• 5-HT7 modulators for CUD

  Research-stage 5-HT7 modulators for the potential treatment of cocaine use disorder.

1. 1Praeventix official websitepraeventix.com
2. 2Praeventix Inc. (United States) - Wikidatawikidata.org